Carl Regillo

About Carl Regillo

Director, Retina Service, Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University, Philadelphia, Pennsylvania, USA

The biggest breakthrough in retina…

It has to be anti-VEGF therapy, and small incision vitrectomy. The former has revolutionized the outcomes of the most common, blinding retinal disease, whereas the latter has made vitreoretinal surgery safer and more efficient.

Your predictions for the field…

We are likely to see effective treatments for advanced dry AMD and GA, as well as the use of gene therapy to treat common retinal conditions.

A technology you would not have been able to live without over the past 10 years…

That would definitely be OCT.

The biggest challenge facing your field in 2022 – and beyond?

The burden of ongoing frequent intravitreal injections for patients.

If you weren’t an ophthalmologist…

I would have pursued interventional cardiology.